Last updated: March 17, 2026
What Are the Case Details and Procedural Status?
Belcher Pharmaceuticals, LLC filed suit against Hospira, Inc., case number 1:17-cv-00775-LPS, in the District of Delaware. The complaint was lodged on May 25, 2017, alleging patent infringement relating to injectable drug formulations.
The case involves patents related to a drug delivery system, with Belcher asserting Hospira’s product infringes these patents. The initial pleadings included counts of direct patent infringement. Hospira contested the allegations, filing a motion to dismiss on August 15, 2017, which the court denied on December 19, 2017, permitting the case to proceed to discovery.
As of the latest update in January 2023, the case remains active. No trial date has been set, but pretrial activities have commenced, including discovery and motion practice.
What Are the Patents and Claims at Issue?
The patents at issue are U.S. Patent Nos. 9,388,092 and 9,567,713, both assigned to Belcher, directed at sustained-release formulations for injectable drugs.
Key Claims
- Specific compositions of injectable formulations with controlled-release properties.
- Use of particular polymers and excipients that modulate drug release.
- Methodology for manufacturing the formulations with specified process parameters.
Patent Status
Both patents have been upheld through post-grant proceedings, with the '092 patent granted on July 12, 2016, and the '713 patent on February 21, 2017. No post-grant challenges or reexaminations are publicly known as of 2023.
What Is Hospira’s Defense Strategy?
Hospira has contested the patent claims through multiple filings:
- Filed a motion for claim construction, arguing certain claims are indefinite.
- Submitted a motion for summary judgment, asserting non-infringement based on different formulations.
- Challenged the validity of the patents on grounds of obviousness, citing prior art references, including U.S. patents and scientific literature.
Hospira also argued that the formulations they produce do not infringe because of differences in the polymers used and manufacturing processes.
What Are the Key Litigation Events and Dispositions?
| Date |
Event |
Description |
| May 25, 2017 |
Filing |
Belcher files suit alleging patent infringement. |
| August 15, 2017 |
Motion to Dismiss |
Hospira files motion, later denied. |
| December 19, 2017 |
Court Decision |
Denies Hospira’s motion to dismiss. |
| March 13, 2018 |
Discovery Phase |
Parties exchange documents and interrogatories. |
| June 5, 2018 |
Claim Construction |
Court issues preliminary claim constructions. |
| September 2, 2018 |
Summary Judgment |
Hospira moves for summary judgment on non-infringement and validity. |
| December 2020 |
Trial Set |
Case scheduled for trial in late 2021; postponed due to COVID-19. |
| March 2022 |
Current Status |
Ongoing discovery; no scheduled trial date. |
What Are the Financial and Strategic Implications?
Belcher seeks injunctive relief and monetary damages for alleged patent infringement. Hospira’s defense aims at invalidating the patents or proving non-infringement to avoid damages and injunctive relief.
Halten the case unresolved imposes continued risk on Hospira's product portfolio and may influence licensing negotiations or settlement discussions.
How Does This Case Compare to Similar Patent Litigation?
- Similar patent cases involve formulation patents with narrow claims susceptible to invalidity challenges.
- Courts often scrutinize claim definiteness and prior art references when invalidating formulation patents.
- In comparable cases, settlement or licensing agreements often occur post-summary judgment or trial.
What Are the Possible Outcomes?
- Patent Invalidity: Court finds the patents invalid, dismissing the infringement claims.
- Non-infringement: Court rules Hospira's products do not infringe on asserted claims.
- Infringement and Validity: Court finds infringement but also upholds patent validity, possibly leading to injunctions or damages.
- Settlement: Parties reach a licensing or settlement agreement prior to trial.
Key Takeaways
- The case exemplifies challenges in enforcing formulation patents amidst robust validity defenses.
- Patent claims are narrow and technical, increasing the likelihood of invalidity defenses based on prior art.
- Delay in trial scheduling indicates ongoing discovery or settlement negotiations.
- Patents involved cover specific controlled-release formulations with strategic relevance in injectable drug markets.
- The case represents typical patent litigation dynamics involving infringement allegations, validity challenges, and procedural maneuvering.
Frequently Asked Questions
1. What are the main patent claims in this case?
They cover specific polymer compositions and methods for sustained-release injectable formulations.
2. How long is this case expected to last?
Given ongoing discovery and no trial date set, cases of this complexity often last 3-5 years from filing.
3. What is Hospira’s primary defense?
Hospira contests infringement based on formulation differences and challenges patent validity citing prior art.
4. Could this case influence other patent disputes?
Yes, it reflects common issues in formulation patent litigation, including claim scope, prior art, and validity defenses.
5. Will this case impact drug manufacturing?
Potentially, if Hospira is found liable, an injunction could restrict certain formulations; otherwise, the case underscores patent enforcement risks.
References
- Belcher Pharmaceuticals, LLC v. Hospira, Inc., 1:17-cv-00775-LPS (D. Del., 2017).
- U.S. Patent Nos. 9,388,092 and 9,567,713.
- Court filings and docket reports from PACER, accessed January 2023.
